Finance

Beta
Lists
IMM:LON
ImmuPharma PLC
GBX 4.50
+3.93%
(+0.17) 1D
Jun 8, 4:35:18 PM GMT+1  ·   GBX
All symbols
SymbolPriceChange% Change
Generating top insights for IMM...
Open
GBX 4.98
High
GBX 5.00
Low
GBX 4.33
Mkt. cap
28.08M
Avg. vol.
1.77M
Volume
2.17M
52-wk high
GBX 19.40
52-wk low
GBX 1.39
EPS
-GBX 0.00
Shares outstanding
623.91M
No. of employees
7
Open
GBX 4.98
High
GBX 5.00
Low
GBX 4.33
Mkt. cap
28.08M
Avg. vol.
1.77M
Volume
2.17M
52-wk high
GBX 19.40
52-wk low
GBX 1.39
EPS
-GBX 0.00
Shares outstanding
623.91M
No. of employees
7
News stories
From sources across the web
About ImmuPharma PLC
CEO-
Employees7
Founded1999
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in GBP
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
345.01K
345.01K
328.10K
328.10K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
245.34K
245.34K
298.97K
298.97K
Operating expense
614.92K
614.92K
652.16K
652.16K
Total operating expenses
614.92K
614.92K
652.16K
652.16K
Operating income
-614.92K
-614.92K
-652.16K
-652.16K
Other non operating income
-
-
184.07K
184.07K
EBT including unusual items
-974.64K
-974.64K
-111.44K
-111.44K
EBT excluding unusual items
-974.64K
-974.64K
-111.44K
-111.44K
Income tax expense
-55.20K
-55.20K
-127.05K
-127.05K
Effective tax rate
5.66%
5.66%
114.00%
114.00%
Other operating expenses
-2.94K
-2.94K
-1.34K
-1.34K
Net income
-919.44K
-919.44K
15.61K
15.61K
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
11.99K
11.99K
367.37K
367.37K
Interest expense
-371.72K
-371.72K
-9.14K
-9.14K
Net interest expenses
-359.72K
-359.72K
358.23K
358.23K
Depreciation and amortization charges
-
-
-
-
EBITDA
-600.66K
-600.66K
-648.78K
-648.78K
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more